Marker Therapeutics, Inc. Income Statement
MRKR|3 years of annual SEC 10-K data (FY2018-FY2021)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
Marker Therapeutics, Inc. reported $0 in revenue and $42M in net loss for FY2021. Revenue increased 16.5% from FY2018 to FY2019.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.64 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2021 | FY2019 | FY2018 |
|---|---|---|---|
| Revenue | $0 | $213.2K | $183.1K |
| SG&A Expense | $12.9M | $10.0M | $6.4M |
| R&D Expense | $27.8M | $12.8M | $5.3M |
| Operating Income | -$39.5M | -$22.5M | -$11.5M |
| Income Tax | - | - | $0 |
| Net Income | -$41.9M | -$21.4M | -$11.0M |
| EPS (Basic) | -$0.61 | - | - |
| EPS (Diluted) | -$0.61 | -$7.75 | -$1.16 |
| Shares Outstanding | 50.7M | 45.4M | 10.6M |
| Operating Margin | - | -10567.3% | -6271.1% |
| Profit Margin | - | -10050.9% | -5999.1% |